Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
Author:
Funder
Natural Science Foundation of Zhejiang Province
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference39 articles.
1. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives;Krasniqi;J Hematol Oncol.,2019
2. Targeted therapeutic options and future perspectives for HER2-positive breast cancer;Wang;Signal Transduct Target Ther.,2019
3. Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer;Gleeson;Expert Opin Biol Ther.,2018
4. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011
5. Incidence of late relapses in patients with HER2-Positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology/NSABP B-31;Chumsri;J Clin Oncol,2019
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care;Current Oncology;2024-03-06
2. 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting;The Lancet Oncology;2022-03
3. Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis;JCO Global Oncology;2021-02
4. Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?;The National Medical Journal of India;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3